Among fit patients with acute myeloid leukemia, the combination of azacitidine plus Venclexta (venetoclax) was associated ...

Azacitidine plus venetoclax (Venclexta) demonstrated significantly improved event-free survival (EFS) vs intensive induction chemotherapy in patients with acute myeloid leukemia (AML), according to ...

First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability ...

KOMZIFTI (ziftomenib), the first and only once-daily oral menin inhibitor for adult patients with R/R AML with a susceptible NPM1 mutation who have no satisfactory alternative treatment options, has ...

A combination of two therapies, azacitidine and venetoclax, or aza-ven, outperformed intensive chemotherapy for acute myeloid leukemia in patients healthy enough to receive aggressive treatment, ...

With the 2025 American Society of Hematology (ASH) Meeting & Exposition kicking off on Saturday, December 6, in Orlando, Florida, Targeted Oncology is bringing you background on the most exciting ...

Regular medical checkups are crucial for early detection and management of cancer recurrence, as demonstrated by the ...

Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States ...

New investigational data from Phase 1/2 study of enzomenib (DSP-5336) in patients with relapsed/refractory acute myeloid leukemia (AML) show clinical ...

Operational real-world data analyzed from patients prescribed ZYNTEGLO™ and LYFGENIA™Data demonstrates the value proposition of one-time, durable gene therapy for the treatment of sickle cell disease ...

Data presented was selected for ASH’s exclusive program to highlight the most impactful research submitted for this year’s meetingReal-world data reinforces the value of durable, one-time gene ...

Syndax Pharmaceuticals, Inc. ( SNDX) The 67th American Society of Hematology ( ASH) Annual Meeting December 8, 2025 7:00 AM EST ...